Market research
NU5.F Solon Eiendom ASA
F EUR Real Estate
Latest close
—
—
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 355M
- P/E ratio
- 7.85
- Analyst target
- 44
- Dividend yield
- 0.0%
- Beta
- 0.47
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Real Estate
- Industry
- Real Estate - Development
- ISIN
- Not available
- Market cap
- 355M
- P/E ratio
- 7.85
- Analyst target
- 44
- Dividend yield
- 0.0%
- Beta
- 0.47
About
About Solon Eiendom ASA
Solon Eiendom ASA acquires, develops, and sells residential real estate properties in Norway. The company was formerly known as Bionor Pharma ASA and changed its name to Solon Eiendom ASA. The company was founded in 2006 and is based in Oslo, Norway. Solon Eiendom ASA is a subsidiary of Samhällsbyggnadsbolaget i Norden AB (publ). As on January 20, 2022, Solon Eiendom ASA was taken private.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the NU5.F discussion.
5 years, 5 months ago
Solon Eiendom ASA is currently in a long term downtrend where the price is trading 0.2% below its 200 day moving average.
From a valuation standpoint, the stock is 62.9% cheaper than other stocks from the Real Estate sector with a price to sales ratio of 2.4.
Solon Eiendom ASA's total revenue sank by 10.3% to $292M since the same quarter in the previous year.
Its net income has dropped by 183.8% to $-42M since the same quarter in the previous year.
Finally, its free cash flow grew by 148.5% to $420M since the same quarter in the previous year.
Based on the above factors, Solon Eiendom ASA gets an overall score of 2/5.